{"id":35674,"date":"2025-06-20T14:36:13","date_gmt":"2025-06-20T06:36:13","guid":{"rendered":"https:\/\/flcube.com\/?p=35674"},"modified":"2025-06-20T14:36:14","modified_gmt":"2025-06-20T06:36:14","slug":"shandong-xinhua-pharma-initiates-phase-ii-study-of-oab-14-for-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35674","title":{"rendered":"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer&#8217;s Disease"},"content":{"rendered":"\n<p>China-based Shandong Xinhua Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/000756:SHE\">SHE: 000756<\/a>) announced the initiation of a Phase II clinical study for its investigational Class 1 chemical drug OAB-14 dry suspension. The trial targets mild-to-moderate Alzheimer&#8217;s disease (AD).<\/p>\n\n\n\n<p><strong>Drug Mechanism and Development<\/strong><br>OAB-14, co-developed by Xinhua Pharma and Shenyang Pharmaceutical University, can significantly reduce the deposition of cerebral \u03b2-amyloid plaque in the brain. It also decreases the excessive phosphorylation of Tau protein and protects the structure and function of cortical and hippocampal neurons and synapses. These actions aim to improve cognition in AD patients.<\/p>\n\n\n\n<p><strong>Clinical Progress<\/strong><br>Phase I results have confirmed OAB-14&#8217;s favorable safety and tolerability in healthy adult subjects. The first Chinese patient has been successfully enrolled in the Phase II clinical study.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/\u65b0\u534e\u5236\u836f\uff1a\u5173\u4e8eOAB-14\u5e72\u6df7\u60ac\u5242\u5b8c\u6210\u2161\u671f\u4e34\u5e8a\u4e2d\u56fd\u9996\u4f8b\u60a3\u8005\u5165\u7ec4\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u65b0\u534e\u5236\u836f\uff1a\u5173\u4e8eOAB-14\u5e72\u6df7\u60ac\u5242\u5b8c\u6210\u2161\u671f\u4e34\u5e8a\u4e2d\u56fd\u9996\u4f8b\u60a3\u8005\u5165\u7ec4\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-11b473ac-6fe8-48ce-a6f3-31447378d22c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/\u65b0\u534e\u5236\u836f\uff1a\u5173\u4e8eOAB-14\u5e72\u6df7\u60ac\u5242\u5b8c\u6210\u2161\u671f\u4e34\u5e8a\u4e2d\u56fd\u9996\u4f8b\u60a3\u8005\u5165\u7ec4\u7684\u516c\u544a.pdf\">\u65b0\u534e\u5236\u836f\uff1a\u5173\u4e8eOAB-14\u5e72\u6df7\u60ac\u5242\u5b8c\u6210\u2161\u671f\u4e34\u5e8a\u4e2d\u56fd\u9996\u4f8b\u60a3\u8005\u5165\u7ec4\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/\u65b0\u534e\u5236\u836f\uff1a\u5173\u4e8eOAB-14\u5e72\u6df7\u60ac\u5242\u5b8c\u6210\u2161\u671f\u4e34\u5e8a\u4e2d\u56fd\u9996\u4f8b\u60a3\u8005\u5165\u7ec4\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-11b473ac-6fe8-48ce-a6f3-31447378d22c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35676,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1174,347],"class_list":["post-35674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-she-000756","tag-xinhua-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer&#039;s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II clinical study for its investigational Class 1 chemical drug OAB-14 dry suspension. The trial targets mild-to-moderate Alzheimer&#039;s disease (AD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35674\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer&#039;s Disease\" \/>\n<meta property=\"og:description\" content=\"China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II clinical study for its investigational Class 1 chemical drug OAB-14 dry suspension. The trial targets mild-to-moderate Alzheimer&#039;s disease (AD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35674\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-20T06:36:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-20T06:36:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2007.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer&#8217;s Disease\",\"datePublished\":\"2025-06-20T06:36:13+00:00\",\"dateModified\":\"2025-06-20T06:36:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674\"},\"wordCount\":139,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2007.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"SHE: 000756\",\"Xinhua Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35674#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35674\",\"name\":\"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer's Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2007.webp\",\"datePublished\":\"2025-06-20T06:36:13+00:00\",\"dateModified\":\"2025-06-20T06:36:14+00:00\",\"description\":\"China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II clinical study for its investigational Class 1 chemical drug OAB-14 dry suspension. The trial targets mild-to-moderate Alzheimer's disease (AD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35674\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2007.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/2007.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer's Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35674#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer&#8217;s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer's Disease - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II clinical study for its investigational Class 1 chemical drug OAB-14 dry suspension. The trial targets mild-to-moderate Alzheimer's disease (AD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35674","og_locale":"en_US","og_type":"article","og_title":"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer's Disease","og_description":"China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II clinical study for its investigational Class 1 chemical drug OAB-14 dry suspension. The trial targets mild-to-moderate Alzheimer's disease (AD).","og_url":"https:\/\/flcube.com\/?p=35674","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-20T06:36:13+00:00","article_modified_time":"2025-06-20T06:36:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2007.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35674#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35674"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer&#8217;s Disease","datePublished":"2025-06-20T06:36:13+00:00","dateModified":"2025-06-20T06:36:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35674"},"wordCount":139,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35674#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2007.webp","keywords":["Clinical trial approval \/ initiation","SHE: 000756","Xinhua Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35674#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35674","url":"https:\/\/flcube.com\/?p=35674","name":"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer's Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35674#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35674#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2007.webp","datePublished":"2025-06-20T06:36:13+00:00","dateModified":"2025-06-20T06:36:14+00:00","description":"China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II clinical study for its investigational Class 1 chemical drug OAB-14 dry suspension. The trial targets mild-to-moderate Alzheimer's disease (AD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35674#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35674"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35674#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2007.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2007.webp","width":1080,"height":608,"caption":"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer's Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35674#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer&#8217;s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2007.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35674"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35674\/revisions"}],"predecessor-version":[{"id":35678,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35674\/revisions\/35678"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35676"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}